Yeruva Sri Lakshmi Hyndavi, Nwabudike Stanley Madu, Ogbonna Onyekachi Henry, Oneal Patricia
Division of Hematology and Oncology, Howard University Hospital, 2041 Georgia Avenue, NW, Washington, DC 20060, USA.
Case Rep Hematol. 2015;2015:784783. doi: 10.1155/2015/784783. Epub 2015 Jun 2.
Aromatase inhibitors (AIs) are most commonly used for breast cancer patients with hormone receptor positive disease. Although the side effect profile of aromatase inhibitors is well known, including common side effects like arthralgia, bone pain, arthritis, hot flashes, and more serious problems like osteoporosis, we present a case of an uncommon side effect of these medications. We report the case of a postmenopausal woman on adjuvant hormonal therapy with anastrozole after completing definitive therapy for stage IIIB estrogen receptor-positive breast cancer, who was referred to hematology service for evaluation of persistent erythrocytosis. Primary and known secondary causes of polycythemia were ruled out. On further evaluation, we found that her erythrocytosis began after initiation of anastrozole and resolved after it was discontinued. We discuss the pathophysiology of aromatase inhibitor-induced erythrocytosis and reference of similar cases reported in the literature.
芳香化酶抑制剂（AIs）最常用于激素受体阳性疾病的乳腺癌患者。尽管芳香化酶抑制剂的副作用已广为人知，包括关节痛、骨痛、关节炎、潮热等常见副作用，以及骨质疏松等更严重的问题，但我们报告了这些药物一种不常见的副作用病例。我们报告了一名绝经后女性的病例，她在完成 IIIB 期雌激素受体阳性乳腺癌的确定性治疗后，接受阿那曲唑辅助激素治疗，因持续性红细胞增多症被转诊至血液科进行评估。排除了真性红细胞增多症的原发性和已知继发性病因。进一步评估发现，她的红细胞增多症在开始使用阿那曲唑后出现，并在停药后缓解。我们讨论了芳香化酶抑制剂诱导的红细胞增多症的病理生理学，并参考了文献中报道的类似病例。
